Welcome to our dedicated page for Veru SEC filings (Ticker: VERU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Veru Inc. (NASDAQ: VERU) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including Forms 8-K and other reports that document material events, capital markets activity, and corporate actions. These filings provide structured insight into how Veru is advancing its late clinical stage biopharmaceutical programs in cardiometabolic and inflammatory diseases, as well as how it manages its capital structure and Nasdaq listing.
Recent Form 8-K filings highlight several key areas. Veru has reported quarterly and full-year financial results, offering details on research and development and general and administrative expenses, operating loss, and net loss from continuing operations. Other 8-Ks describe a 1-for-10 reverse stock split of the company’s common stock, explaining how the split affected issued and outstanding shares while leaving authorized share counts and par value unchanged, and confirming that VERU continues to trade on the Nasdaq Capital Market.
Filings also document Veru’s capital raising transactions. An October 2025 Form 8-K outlines an underwriting agreement for an underwritten public offering of common stock (or pre-funded warrants) and accompanying Series A and Series B warrants, with expected net proceeds of approximately $23.4 million. The company states that these proceeds are intended to support development of enobosarm, particularly the planned Phase 2b PLATEAU clinical study, and to provide working capital and funds for general corporate purposes.
Other 8-Ks cover Nasdaq listing compliance, including a letter from Nasdaq’s Listing Qualifications Department indicating that Veru regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), closing a prior deficiency matter. Additional filings describe a Settlement Agreement and Release with Onconetix, Inc. resolving payment obligations under promissory notes through a combination of cash, Series D Convertible Preferred Stock, and warrants.
Through Stock Titan, users can access Veru’s SEC filings and take advantage of AI-powered summaries that explain the significance of each document. These tools help clarify how specific filings relate to Veru’s enobosarm and sabizabulin programs, its financing strategy, reverse stock split, listing status, and other corporate developments. Investors can quickly locate 8-Ks that discuss clinical milestones, capital raises, and governance changes, as well as cross-reference these disclosures with Veru’s broader cardiometabolic and inflammatory disease pipeline.
Veru Inc. filed a preliminary prospectus supplement for a primary offering of common stock and, in lieu of shares for certain investors, pre-funded warrants, together with accompanying Series A and Series B common stock warrants. The filing also covers the shares issuable upon exercise of these warrants.
The company states it will receive the proceeds from this offering and intends to use them primarily to fund the planned Phase 2b PLATEAU clinical study of enobosarm in combination with GLP‑1 RA therapy, as well as for working capital and general corporate purposes. Pre-funded warrants are immediately exercisable at $0.001 per share. Series A warrants are immediately exercisable and expire five years from issuance. Series B warrants are immediately exercisable and expire on the earlier of a data/price milestone or three years. The warrants will not be listed, which may limit liquidity.
Shares outstanding were 14,650,392 as of June 30, 2025. The company effected a 1‑for‑10 reverse stock split on August 8, 2025. Veru’s common stock last closed at $3.65 on October 28, 2025.
Michael L. Rankowitz, a director of VERU Inc. (VERU), reported an acquisition of equity-linked compensation on 10/01/2025. The filing records the grant of 7,000 common stock options with an exercise price of $3.89, exercisable beginning 10/01/2026 and expiring 10/01/2035.
The options vest in three equal installments, with one-third vesting on each of 10/01/2026, 10/01/2027, and 10/01/2028. After the reported transaction the filing shows beneficial ownership of 7,000 shares/options held directly. The Form 4 was signed via power of attorney by Phil R. Greenberg on 10/03/2025.
Hyun Grace, a director of VERU Inc. (VERU), reported an acquisition of 3,000 non‑derivative shares resulting from the exercise/issuance of options on 10/01/2025. The options have an exercise price of $3.89, are exercisable beginning 10/01/2026 and expire on 10/01/2035. Following the reported transaction the filing shows 3,000 shares beneficially owned directly by the reporting person.
The form discloses a vesting schedule: one‑third of the options vest on each of 10/01/2026, 10/01/2027 and 10/01/2028. The Form 4 was signed on behalf of the reporting person by power of attorney on 10/03/2025. All details above are taken directly from the filing and no additional inferences are made.
Veru Inc. (VERU) director reports stock option grant. On 10/01/2025, the reporting person acquired an option to purchase 6,000 shares of common stock at an exercise price of $3.89 per share. The option expires on 10/01/2035. One-third of the shares vest on each of 10/01/2026, 10/01/2027, and 10/01/2028. Following the transaction, 6,000 derivative securities were beneficially owned, held directly. The option was reported at a price of $0, indicating an award rather than an open-market purchase.
Veru Inc. reported that amounts owed under two promissory notes issued by Onconetix, Inc. (formerly Blue Water Vaccines) totaling $8,826,155.41 as of September 22, 2025 were settled under a Settlement Agreement and Release. Under the settlement the company received $6,326,155.41 in cash, 3,125 shares of Onconetix Series D Convertible Preferred Stock (stated value $1,000 per share) and 846,975 warrants to purchase Onconetix common stock, and the promissory notes and the amended forbearance agreement terminated on payment.
The Series D Preferred is convertible (including at Veru's option) into Onconetix common stock, carries certain registration rights and may be redeemable by the borrower in specified circumstances. Veru states there is no assurance it will realize cash proceeds from the preferred shares, warrants, or any common stock acquired on exercise of the warrants. The full Settlement Agreement is filed as Exhibit 10.1.
Veru Inc. notified Nasdaq on August 26, 2025 that it has regained compliance with Nasdaq's minimum $1.00 bid price requirement for continued listing, and Nasdaq has closed the related matter. The earlier notice of noncompliance was issued August 29, 2024 because Veru's common stock had not maintained a minimum bid of $1.00 for 30 consecutive business days. Nasdaq originally gave Veru 180 calendar days to regain compliance, which was later extended to August 25, 2025. This 8-K confirms the company met the minimum bid price threshold by the extended deadline and the listing deficiency is resolved.
Veru Inc. reported a quarterly net loss of $7.33 million for the three months ended June 30, 2025, narrower than the prior-year quarter loss of $10.97 million, driven by lower operating expenses with research and development falling to $3.02 million and selling, general and administrative to $5.01 million. The company recorded no net revenues in the quarter and reported net loss per share of $0.50 versus $0.75 a year earlier.
Cash and restricted cash totaled $15.01 million at June 30, 2025, down from $24.92 million at September 30, 2024. Net cash used in operating activities for the nine months was $24.55 million. The company completed the sale of its FC2 business, generating expected net proceeds of approximately $16.3 million and recognizing a $4.3 million loss on the sale, and recognized an $8.6 million gain on extinguishment of debt related to the residual royalty agreement. Management discloses substantial doubt about the Company’s ability to continue as a going concern for at least twelve months.
Veru Inc. effected a 1-for-10 reverse stock split of its common stock, effective 11:59 pm CT on August 8, 2025, converting every ten pre-split shares into one post-split share. The Nasdaq listing will trade on a split-adjusted basis beginning with the opening of trading on or about August 11, 2025, under the same ticker VERU and new CUSIP 92536C202. Fractional shares will not be issued; shareholders will receive cash in lieu of any fractional interest.
The split does not change the number of authorized shares or par value. The Board approved the 1-for-10 ratio after shareholders authorized a 1-for-2 to 1-for-20 range at a July 25, 2025 special meeting. Outstanding equity awards and reserved shares under the Company’s Schedules of equity plans were proportionately adjusted and the Company’s Form S-8 registration statements were amended by operation of Rule 416(b).
Veru Inc. filed a current report stating that it issued a press release announcing its financial results for the quarter and nine months ended June 30, 2025. The press release is included as Exhibit 99.1 and provides the detailed figures and commentary on the company’s performance for this period. The report clarifies that this information is being furnished rather than filed under securities law, which affects how it may be used in future legal and regulatory contexts.